文献速递间质性肺疾病

Taladegib治疗特发性肺纤维化:一项多中心随机双盲安慰剂对照2a期试验

Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.
PubMed 文献 · Lancet Respir Med · 2025-09-30

ENV-IPF-101是一项在5国16中心开展的2a期试验,41例未接受抗纤维化治疗的IPF患者随机接受taladegib 200 mg或安慰剂治疗12周。

要点

  • taladegib 200 mg每日一次治疗12周,FVC占预计值百分比改善优于安慰剂。
  • 常见不良事件为味觉障碍、肌肉痉挛和脱发,均为1-2级,无严重不良事件。
  • HRCT总肺容量和定量ILD百分比等影像学指标也显示taladegib优于安慰剂。

核心结论

  • taladegib在IPF患者中显示出可接受的安全性,并改善FVC和多项HRCT纤维化指标,支持进一步开展2b期试验。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2a期概念验证试验,在澳大利亚、加拿大、马来西亚、墨西哥和韩国16个中心开展。
  • 纳入41例40岁以上、未接受同期IPF治疗的IPF患者,随机分配至taladegib 200 mg每日一次口服或安慰剂等效治疗12周,随访6周。
  • 主要结局为意向治疗人群的安全性和疗效可评估人群的FVC较基线变化,探索性结局为HRCT纤维化指标。

主要发现

  • taladegib组21例(女性3例[14%],男性18例[86%]),安慰剂组20例(女性4例[20%],男性16例[80%])。
  • 所有可能与研究药物相关的治疗中出现不良事件均为1级或2级,除1例外均为轻中度,无严重不良事件。
  • taladegib组最常见不良事件为味觉障碍(12/21[57%])、肌肉痉挛(12/21[57%])和脱发(11/21[52%]),安慰剂组均未报告。
  • 安慰剂组最常见不良事件为腹泻(4/20[20%])、头痛(3/20[15%])和头晕(1/20[5%])。

关键数值与推荐

  • 试验期间无死亡发生。

临床怎么用

  • taladegib为Hh通路抑制剂,可能为未接受抗纤维化治疗的IPF患者提供新的治疗选择,但需2b期试验进一步验证。

局限性

  • 样本量小(共41例),为2a期概念验证试验。
  • 仅纳入未接受同期IPF治疗的患者,随访12周加6周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The hedgehog (Hh) signalling pathway promotes fibrosis in idiopathic pulmonary fibrosis (IPF), an interstitial lung disease with a high mortality rate. Currently, there is no cure for IPF, and available anti-fibrotics only slow the rate of decline in lung function in IPF. We aimed to assess the safety and efficacy of taladegib (ENV-101), an Hh pathway inhibitor, in IPF in a phase 2a, proof-of-concept clinical trial. METHODS: ENV-IPF-101 was a randomised, double-blind, placebo-controlled, phase 2a trial conducted at 16 clinical sites in Australia, Canada, Malaysia, Mexico, and South Korea for patients with IPF older than 40 years who were not treated with concurrent IPF therapy. Patients were randomly assigned to taladegib 200 mg or placebo equivalent once daily, orally for 12 weeks, with a 6-week follow-up. The primary outcomes were safety in the intention-to-treat population and change from baseline in forced vital capacity (FVC) in the efficacy-evaluable population. Exploratory outcomes were measures of fibrosis on high-resolution CT (HRCT) in the efficacy-evaluable population. This study is registered with ClinicalTrials.gov, NCT04968574. FINDINGS: Between Aug 12, 2021, and July 28, 2023, 41 patients were randomly assigned to the taladegib group (n=21; three [14%] female and 18 [86%] male) or the placebo group (n=20; four [20%] female and 16 [80%] male). All treatment-emergent adverse events possibly or probably related to the study drug were grade 1 or 2, all except one were mild or moderate in severity, and none were serious adverse events. The most common treatment-emergent adverse events in the taladegib group were dysgeusia (12 [57%] of 21), muscle spasms (12 [57%] of 21), and alopecia (11 [52%] of 21); none of these events were reported in the placebo group, for which the most common adverse events reported were diarrhoea (four [20%] of 20), headache (three [15%] of 20), and dizziness (one [5%] of 20). Patients treated with taladegib had an improvement from baseline in FVC and across multiple HRCT-based measures of disease. Between-group differences in change from baseline to week 12 favoured taladegib for the efficacy measures of percent predicted FVC (3·95% [95% CI 0·31-7·60]; p=0·035; mean change from baseline of 1·9% in the taladegib group vs -1·3% for placebo), total lung capacity by HRCT (257·0 mL [95% CI 86·8-427·2]; p=0·0040; mean change from baseline of 206·67 mL in the taladegib group vs -55·58 mL in the placebo group), and percent quantitative interstitial lung disease (p=0·047; mean change from baseline of -9·4% in the taladegib group vs 1·1% in the placebo group). No deaths occurred during the trial. INTERPRETATION: The acceptable safety profile and efficacy analyses of taladegib support further investigation in a phase 2b trial in patients with IPF (WHISTLE-PF). FUNDING: Endeavor BioMedicines.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Maher TM, Goldin JG, Hood J, et al. Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025. PMID: 41043447. doi:10.1016/S2213-2600(25)00239-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。